ER JEG BERETTIGET TIL DENDRITISK CELLETERAPI?
AM I ELIGIBLE FOR DENDRITIC CELL THERAPY?
For at forbedre eller helbrede kræft ved hjælp af dendritiske celler er arbejdsmekanismen stort set den samme og effektiv i enhver kræft, der danner vævsstrukturer (tumorer, karcinomer, melanomer, sarkomer osv.). Dette gør alle kræftpatienter – herunder alle kræftformer, der danner en fast tumor eller karcinom, herunder metastaser – berettigede bortset fra visse former for leukæmi. Da behandlingseffekten er naturlig, virker den i alle faser af kræftrejsen, og den kan bruges sammen eller adskilt fra enhver anden behandling. Onkologer med ekspertise inden for immunologi vil sandsynligvis foreslå dendritisk celleterapi som en første og primær terapi. For klarhedens skyld er DCT, i modsætning til kemoterapi, en primær terapi, mens de fleste mener, at DCT kun er en supplerende terapi. For at bestemme den bedste strategi diskuterer vi gerne din individuelle situation baseret på dine medicinske rapporter.
To improve or cure cancer using dendritic cells, the work mechanism is pretty much the same and effective in any cancer that forms tissue structures (tumours, carcinomas, melanomas, sarcomas etc.). This makes every cancer patient – including all cancer types that form a solid tumour or carcinoma, including metastasis – eligible apart from some forms of leukaemia. As the treatment effect is natural, it works in every stage of the cancer journey and it can be used in conjunction or separate from any other treatment. Oncologists with expertise in immunology will likely suggest dendritic cell therapy as a first and primary therapy. For clarity DCT, unlike chemotherapy, is a primary therapy, while most believe DCT is just an adjunctive therapy. To determine the best strategy, we are happy to discuss your individual situation based on your medical reports.